Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors

Autor: Juan Bernal, David Andreu, Wioleta Kowalczyk, Ana Garzón, Leticia González-Cintado, Gloria Calderita, Thomas Zurcher, Margarita Rodríguez, Ignacio Torres, Virgínia Gondar, Carlos Ardavín, Juan Martin Caballero, Cayetano Von Kobbe
Přispěvatelé: Instituto Madrileño de Investigación y Desarrollo Rural, Agrario y Alimentario, Comunidad de Madrid, Ministerio de Educación (España), Ministerio de Industria, Turismo y Comercio (España), Ministerio de Ciencia e Innovación (España)
Předmět:
medicine.medical_treatment
Papillomavirus E7 Proteins
Cancer Treatment
lcsh:Medicine
Uterine Cervical Neoplasms
Adaptive Immunity
Infectious bursal disease virus
Biochemistry
Infectious bursal disease
Mice
Cancer immunotherapy
Papil·lomavirus -- Malalties
lcsh:Science
Immune Response
Human papillomavirus 16
Vaccines
Multidisciplinary
Vaccination
Infectious Diseases
Oncology
Medicine
Female
Immunotherapy
Adjuvant
Research Article
Biotechnology
Human Papillomavirus Infection
Immunology
Sexually Transmitted Diseases
Mice
Transgenic
Biology
Papillomavirus Vaccines
Immune system
Antigen
Vaccine Development
medicine
Animals
Vaccines
Virus-Like Particle
Úter -- Càncer
lcsh:R
Papillomavirus Infections
Immunity
Cancer
Proteins
Major Histocompatibility Antigens
medicine.disease
Virology
Bionanotechnology
lcsh:Q
Clinical Immunology
Zdroj: Recercat. Dipósit de la Recerca de Catalunya
instname
Digital.CSIC. Repositorio Institucional del CSIC
PLoS ONE
PLoS ONE, Vol 7, Iss 12, p e52976 (2012)
Popis: Cervical cancer is caused by persistent high-risk human papillomavirus (HR-HPV) infection and represents the second most frequent gynecological malignancy in the world. The HPV-16 type accounts for up to 55% of all cervical cancers. The HPV-16 oncoproteins E6 and E7 are necessary for induction and maintenance of malignant transformation and represent tumor-specific antigens for targeted cytotoxic T lymphocyte-mediated immunotherapy. Therapeutic cancer vaccines have become a challenging area of oncology research in recent decades. Among current cancer immunotherapy strategies, virus-like particle (VLP)-based vaccines have emerged as a potent and safe approach. We generated a vaccine (VLP-E7) incorporating a long C-terminal fragment of HPV-16 E7 protein into the infectious bursal disease virus VLP and tested its therapeutic potential in HLA-A2 humanized transgenic mice grafted with TC1/A2 tumor cells. We performed a series of tumor challenge experiments demonstrating a strong immune response against already-formed tumors (complete eradication). Remarkably, therapeutic efficacy was obtained with a single dose without adjuvant and against two injections of tumor cells, indicating a potent and long-lasting immune response. © 2012 Martin Caballero et al.
Instituto Marileño de Desarrollo; Comunidad Autonoma de Madrid; Ministerio de Educacion; Ministerio de Industria, Turismo y Comercio; Ministerio de Ciencia e Innovacion
Databáze: OpenAIRE
Externí odkaz: